A Phase I study of bortezomib plus irinotecan in patients with advanced solid tumors (Q33373147)

26 July 2017

A Phase I study of bortezomib plus irinotecan in patients with advanced solid tumors (English)

1 reference

26 July 2017

1 reference

Leonard J Appleman

6

0 references

Robert Z Orlowski

9

object named as

Robert Z Orlowski

1 reference

26 July 2017

5

E Claire Dees

1 reference

26 July 2017

2

Bert H O'Neil

1 reference

26 July 2017

David P Ryan

1

1 reference

26 July 2017

Jeffrey G Supko

3

1 reference

26 July 2017

Carlo M Rocha Lima

4

1 reference

26 July 2017

Jeffrey Clark

7

1 reference

26 July 2017

Phinos Fidias

8

1 reference

26 July 2017

Oscar Kashala

10

1 reference

26 July 2017

Joseph P Eder

11

1 reference

26 July 2017

James C Cusack

12

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 December 2006

1 reference

26 July 2017

1 reference

26 July 2017

107

1 reference

26 July 2017

11

1 reference

26 July 2017

2688-2697

1 reference

Development of the proteasome inhibitor PS-341.

26 July 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22280

7 January 2021

Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22280

7 January 2021

Proteasome-dependent regulation of p21WAF1/CIP1 expression

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22280

7 January 2021

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22280

7 January 2021

Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22280

7 January 2021

Peritoneal carcinomatosis: what can we do about it?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22280

7 January 2021

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22280

7 January 2021

A phase 2 study of bortezomib in relapsed, refractory myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22280

7 January 2021

Phase II trial of bortezomib for patients with advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22280

7 January 2021

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22280

7 January 2021

First proteasome inhibitor approved for multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22280

7 January 2021

26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22280

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22280

7 January 2021

Mechanisms of resistance to topoisomerase I-targeting drugs

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22280

7 January 2021

Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22280

7 January 2021

Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22280

7 January 2021

Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22280

7 January 2021

Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22280

7 January 2021

Cancer cell adaptation to chemotherapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22280

7 January 2021

Expression of multidrug transporter MRP4/ABCC4 is a marker of poor prognosis in neuroblastoma and confers resistance to irinotecan in vitro.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22280

7 January 2021

Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22280

7 January 2021

Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22280

7 January 2021

Identifiers

DOI

10.1002/CNCR.22280

1 reference

release_xmrvqa57azdjxc45lufaziceni

26 July 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/xmrvqa57azdjxc45lufaziceni

24 November 2022

mapped directly with Wikidata item

1 reference